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ABSTRACT
OBSErve Germany was the first observational
study of belimumab as add-on treatment for
systemic lupus erythematosus (SLE) in routine
clinical care in Germany, retrospectively
collecting data from 102 SLE patients,
6 months before and after belimumab
initiation. Most patients had moderate or
severe SLE and several SLE manifestations.
After 6 months of belimumab treatment, 78%
of patients showed an improvement in overall
disease activity of at least 20% in their
physician’s judgment and for 42% of patients
the improvement was at least 50%. Similar
results were observed for the most common
manifestations: arthritis, fatigue, rash, alopecia,
increased anti-dsDNA antibody levels, and low
complement. The SLE Disease Activity Index
(SLEDAI/SELENA-SLEDAI) decreased from 10.6
to 5.6 (n = 65), with other indices also showing
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improvement. A notable dose reduction was
seen for concomitant oral corticosteroids, from
13.7 to 7.6 mg/day overall (n = 91), and from
17.5 to 8.6 mg/day in patients with a high
corticosteroid dose at belimumab initiation
(C7.5 mg; n = 63). Six patients discontinued
belimumab therapy within 6 months. Overall,
belimumab showed promising results for SLE
patients in real-world settings. After 6 months
of belimumab treatment, disease activity and
corticosteroid use were reduced. The
discontinuation rate was low and belimumab
appeared to be well tolerated.
Funding GlaxoSmithKline UK.
Keywords: B cell targeted therapy; Belimumab;
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INTRODUCTION
Systemic lupus erythematosus (SLE) is an
autoimmune disease with heterogeneous
morbidities, involving the skin, joints, kidneys,
or central nervous system. The clinical course is
characterized by chronic remitting and relapsing
phases which usually requires life-long
medication to manage disease activity. Standard
medications for SLE include oral corticosteroids,
antimalarials, cytotoxic agents, non-steroidal
anti-inflammatory drugs (NSAIDs), and
immunomodulators/immunosuppressors, some
of which can lead to severe side effects,
especially at higher doses [1–7]. Potentially
severe complications of SLE include lupus
nephritis and central nervous system vasculitis,
both of which require long-term treatment with
high doses of corticosteroids and/or
cyclophosphamide and tend to relapse [1, 8].
The combination of SLE manifestations and side
effects of long-term medication use can severely
impact on the patients’ quality of life and ability
to work. However, advances in therapy and
management have increased life expectancy and
quality of life for SLE patients [9, 10].
New types of therapies include biologicals
[11, 12], e.g., the BLyS (B lymphocyte
stimulator) inhibitor belimumab (trade name
Benlysta), a human monoclonal IgG1k
antibody that is indicated for adult
autoantibody-positive SLE patients that require
an add-on to other SLE medications due to a
persisting high degree of disease activity despite
standard therapy, e.g., in cases with
ineffectiveness or intolerability of other
medications [13]. Belimumab received market
authorization for Europe and the USA in 2011,
after safety and efficacy were confirmed in two
randomized, placebo-controlled clinical trials
[14–18], subsequently followed by an ongoing
continuation study [19]. At this stage, it is
essential to evaluate how the results of these
studies translate into the clinical reality of
managing and treating SLE patients.
BLyS is an essential B cell survival factor acting
by binding to specific B cell surface receptors. In
SLE, an excess concentration of BLyS inhibits the
physiological apoptosis of autoreactive B cells and
promotes their pathological differentiation into
autoantibody-producing plasma cells.
Belimumab acts by capturing and inhibiting
soluble BLyS before it binds to its receptors, thus
indirectly inhibiting the survival and
differentiation of autoreactive B cells, as well as
the subsequent production of autoantibodies by
plasma cells [20, 21]. Belimumab is a long-term
treatment administered as an intravenous
infusion, with the initial three doses given every
2 weeks (week 0, 2, 4) followed by 4-weekly
administrations. Clinical response has been
described as early as 8 weeks [22]. However,
generally patients should be treated for
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6 months before a decision about treatment
discontinuation due to lack of response is taken
[13]. Patients with high disease activity levels
despite standard therapy have been shown to
benefit most from belimumab treatment,
especially regarding clinical disease activity (e.g.,
as measured by validated scores), corticosteroid
dependence, and laboratory markers such as
autoantibody-positivity or low complement
levels [16].
OBSErve is a multinational study
programme with results having been reported
from the USA and Spain so far [23, 24]. The
present study, OBSErve Germany (Evaluation
Of Use of Belimumab in Clinical Practice
Settings; GSK study number GSK 117214), is
part of this programme and the first real-world
observation of belimumab use and outcomes
in routine clinical care in Germany, 2 years
after belimumab was launched on the
European market. Further OBSErve studies are
under way or planned in other European and
Latin American countries. The objective of the
study was to observe the overall patterns of SLE
care and outcomes among belimumab users in
clinical practice in Germany and to describe
the belimumab patient population, the reasons
for initiating and discontinuing belimumab
treatment, aspects of healthcare resource
utilization in these patients, and the use of
routine disease assessment tools in clinical
practice. After the clinical trials confirmed
efficacy and safety in an interventional
setting, it is important to investigate usage
patterns and disease management results for
patients in routine care, as assessed by their
treating physicians [25]. For this study,
treatment results were analyzed after the
initial 6 months of belimumab therapy, in
line with the summary of product
characteristics for belimumab which
recommends a minimum treatment period of
6 months before a decision about the




OBSErve Germany was a retrospective,
multicenter, observational cohort study
collecting data on belimumab therapy in
routine care of SLE patients in Germany. It
was designed to gather real-world information
from patient medical records on the short-term
(6 months) clinical outcome in SLE patients
treated with belimumab. The study was
conducted in line with the Guidelines for
Good Pharmacoepidemiology Practices (GPP).
All study documents were submitted to the
responsible ethics committee (EC) of the local
coordinating investigator, i.e., the
Landesaerztekammer Rheinland-Pfalz.
According to the local requirements, the
observational plan was notified to the
competent higher federal authority, the Paul
Ehrlich Institute (PEI) before starting data
collection. Data collection for the study was
performed between April 2013 and November
2013 in 21 rheumatology practices. During the
data collection period, monthly update reports
on the participating physicians were provided
to the Federal Association of Panel Doctors
(KBV), the Central Federal Association of the
Health Insurance Funds (GKV-Spitzenverband),
and the Association of Private Health Insurance
Funds (PKV) according to national law AMG
§67(6). As a result of its retrospective character,
this study did not influence the physicians’
treatment decisions; frequency and timing of
examinations and the prescription of
belimumab were handled according to the
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physician’s routine practice and no additional
examinations were required for the study.
Therefore patient’s informed consent was not
required.
Study Population
OBSErve Germany was sponsored by GSK who
contributed their knowledge about sites with
experience in prescribing belimumab to be
contacted with a feasibility questionnaire.
According to the predefined eligibility criteria,
the study sample included clinical sites which had
at least 5 years of experience in treating SLE
patients and at least 6 months experience in the
usage of belimumab for SLE. At the start of the
study the participating physicianswere required to
be managing at least ten SLE patients at the time
and to have initiated belimumab in at least two
patients as part of routine care, with at least one of
them still receiving belimumab at the time.
Patients included in the documentation had
to be at least 18 years old and belimumab-naı¨ve
with a confirmed diagnosis of SLE. For these
patients, treatment with belimumab had to be
initiated as part of routine care at least
6 months before inclusion into the study,
ensuring a purely retrospective observation
and documentation of the first 6 months of
the treatment. All eligible patients had to be
included at each site, also if they discontinued
belimumab therapy within the initial 6 months,
in order to also obtain insight into the
frequency and reasons for early
discontinuation in a real-world setting. Data
that had to be available included medical and
treatment history for at least 6 months prior to
belimumab initiation, the reason for
belimumab initiation, treatment outcomes at
6 months after start of treatment, and the
reason for discontinuation if belimumab was
discontinued. Exclusion criteria were current
enrollment in an SLE-related trial or initiation
of belimumab therapy as part of a clinical trial
interventional arm.
Study Conduct
For this study, the index date was defined as the
date of belimumab initiation. The study period
included a treatment history period of
6 months prior to the index date followed by
the initial belimumab treatment period of
6 months after the index date. This allowed
for an observation time of about 12 months for
each patient in the study. The participating
physicians identified all adult SLE patients in
their practices who fulfilled the eligibility
criteria, to avoid selection bias. The physicians
collected and documented the relevant
information from their patients’ medical
records in anonymized form. Information on
the physicians’ practices and their SLE
management approaches were collected,
including practice type, patient caseload, and
routine SLE diagnosis and management
approaches. The following patient data from
medical records were captured in the patient
case report form (CRF): patient demographics,
co-morbidities, SLE disease characteristics at
start of belimumab therapy, belimumab
therapy, other SLE and non-SLE medications,
outcomes related to clinical and serological
manifestations, disease activity assessments,
physician judgment on overall clinical
response 6 months after initiation, and
healthcare resource utilization.
All assessment results regarding disease
activity and outcome (e.g., the ‘‘Safety of
Estrogens in Lupus Erythematosus National
Assessment’’ (SELENA) modification of the SLE
Disease Activity Index (SLEDAI)) were estimated
by the participating physicians themselves,
either immediately during a patient’s visit, or
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retrospectively from the patient chart. At the
time of initiating belimumab the scoring used
ranged from mild, moderate to severe lupus.
Regarding the treatment effects 6 months after
belimumab the physicians’ judgment scale for
disease activity, overall as well as based on
disease manifestations ranged from worse, no
improvement, less than 20% improvement (i.e.,
minimally improved), 20–49% improvement
(i.e., clear but moderate improvement),
50–79% improvement (i.e., great
improvement) to at least 80% improvement
(i.e., nearly normalized). This estimated score
was also the primary endpoint measure to
reflect the physicians’ opinion of the
improvement of their patients’ SLE status. This
scale was not a validated instrument but aimed
to reflect the real-world clinical approach for
the evaluation of treatment effectiveness, where
formal instruments to assess disease activity
(such as the SLEDAI or ECLAM (European
Consensus Lupus Activity Measurement
Index)) are not yet broadly used on a regular
basis, despite recommendations by the
European League Against Rheumatism
(EULAR) [26]. Therefore, the physicians’
judgment scale, used identically across the
whole OBSErve study programme, aimed to
obtain a subjective clinical rating.
Additionally, disease assessments using
Physician Global Assessment Scales and
Patient Global Assessment Scales were
collected where available. The physicians who
documented results from these scales used their
internal rating system and the results were then
converted to a scale ranging from 0 to 100,
based on the ranges provided by the physicians.
Data collection was performed using an
electronic data capture system (EDC).
Automatic checks were implemented in the
EDC to avoid missing answers and to provide
valid and plausible data entries. During the
study it was discovered that data related to
concomitant SLE medication were incomplete.
Thus, queries were sent out to the respective
physicians to confirm and to complete the
provided information.
Data Analysis
All statistical analyses were performed in a
descriptive manner and were interpreted in an
explorative way. Tables were created with the
software SAS version 9.2 for Windows. For
continuous data, the number of non-missing and
missing values, mean, standard deviation,
minimum, median, and maximum were
calculated. For the analysis of corticosteroid doses
and for SLEDAI/SELENA-SLEDAI response groups,
values of continuous variables were additionally
presented as categorical data. The analysis
included all valid cases (fulfilling the inclusion
criteria, CRFs completed) from eligible sites
(fulfilling the inclusion criteria). The evaluation
of treatment outcome data after 6 months was
performed for all patients who completed the
initial 6 months of belimumab therapy, in line
with the summary of product characteristics for
belimumabwhichrecommendsaminimuminitial
treatment period of 6 months [13].
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
Baseline Characteristics of Study Sites
For this study, SLE patient data and treatment
outcomes under belimumab therapy were
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collected retrospectively for 102 patients from
21 sites in Germany, mainly hospitals (76%).
On average (mean ± standard deviation), the
physicians’ experience in treating SLE patients
was 15.7 ± 6.74 years (min 5, max 30 years).
They were treating 72.7 ± 30.51 SLE patients
(min 20, max 100 patients) at the time of data
collection. Each physician, on average, was
treating 5.7 ± 4.73 patients with belimumab.
Of these, 4.8 ± 2.17 patients had been receiving
belimumab for at least 6 months.
The most common disease assessment tools
used routinely by the study sites for SLE
management were the SLEDAI (57%)/
SELENA-SLEDAI (29%), the Patient Global
Assessment Scale (43%), the ECLAM (38%),
and the Physician Global Assessment Scale
(33%). Furthermore, the most frequent routine
laboratory analyses included testing of C3 and
C4 concentrations (performed by 100% of
physicians), serum creatinine levels (100%),
C-reactive protein levels (95%), as well as a
complete blood count (95%). The majority of
participating physicians (62%) stated that the
patient’s opinion was highly important when
considering changes in the individual SLE
therapy.
Patient Baseline Characteristics
and Reasons for Initiating Belimumab
Therapy
A total of 102 patients were included in the
analysis. Most of them were female (91%) and
all but one were Caucasian. The mean age of the
patients was 42.5 ± 13.83 years (min 19, max
76) and the mean body mass index was
25.3 ± 6.19 kg/m2. The SLE-related baseline
data and the co-morbidities of the patients are
provided in Table 1.
The patients’ SLE disease severity before
initiating belimumab treatment, i.e., at
baseline, was assessed by their physician. The
majority of patients had moderate (60%) or
severe (25%) SLE and most (58%) had been
diagnosed with SLE more than 10 years ago. The
most common laboratory findings for these
patients at baseline were high levels of
anti-dsDNA antibodies (in 72% of patients)
and below-normal levels of the complement
components 3 (61%) and 4 (52%).
The number of clinical and serological
manifestations of SLE varied in the study
population, but for 60% of patients, four or
more manifestations were documented at
baseline. The most frequently documented SLE
manifestations at baseline were arthritis (67% of
patients), increased anti-dsDNA antibody levels
(56%), low complement levels (47%), rash
(40%), lupus nephritis (25%), and alopecia
(25%). The most frequently listed co-morbid
conditions of the patients at the start of
belimumab therapy were fatigue (41%),
hypertension (35%), osteoporosis (20%), and
depression (12%).
The indication for belimumab was related to
mucocutaneous, arthritis, serositis, and mild
lupus nephritis occurring with other lupus
manifestations. The most common reason for
initiating belimumab therapy was
ineffectiveness of the patient’s previous
treatment regimen (88% of patients). Further
common reasons were a worsening of the
patient’s condition (61%) and a desire to
decrease the use of corticosteroid drugs
(‘‘steroid sparing’’) (40%).
SLE Disease Activity at Baseline
The following comparisons of results from
baseline to 6 months later are presented for all
96 patients who completed the initial 6 months
of treatment. This reflects the recommendation
made by the European regulatory authority (the
276 Rheumatol Ther (2016) 3:271–290















Laboratory values at start of belimumab therapyb
High anti-dsDNA antibody titresc 73 72
Low complement component 3 (\lower limit of normal)c 62 61
Low complement component 4 (\lower limit of normal)c 53 52
Proteinuria ([upper limit of normal) 30 29
Leukopenia 17 17
Thrombocytopenia 15 15
Hemolytic anaemia 6 6
None of these 9 9








SLE manifestations at start of belimumab therapy (most frequent)b
Arthritis 68 67
Increased anti-dsDNA antibody levelsc 57 56
Low complement levels (C3, C4, or CH50)c 48 47
Rash 41 40
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European Medicines Agency, EMA), and laid
down in the summary of product characteristics
for belimumab, to initially administer
belimumab for at least 6 months before
evaluation of the treatment result and before
any decision about continuation of the
treatment [13]. Six patients discontinued the
study before this time point (see details below).
A formal tool to measure disease activity was
used for 76 patients (79%), at baseline and after
the initial 6 months of belimumab therapy.
Here, the physicians most frequently reported
SLEDAI/SELENA-SLEDAI scores (for 65 patients;
score range from 0 (no disease activity) to 105),
with a mean score of 10.6 ± 6.09 at baseline
(min 0, max 28), followed by the ECLAM (for 19
patients; range from 0 (no disease activity) to
10), with a mean score of 2.9 ± 2.03 (min 0,
max 7). The Physician Global Assessment Scale
was used for 17 patients (range from 0 (no
disease activity) to 100) and the mean baseline
score was reported as 71.9 ± 13.56 (min 30, max
88), and the Patient Global Assessment Scale














Reasons for start of belimumab therapyb
Previous treatment regimen not effective 90 88
Patient condition worsening 62 61
Decrease use of corticosteroids (steroid sparing) 41 40
Previous treatment regimen not well tolerated 27 26
Previous treatment regimen inconvenient 3 3
Myositis 1 1
CH50 total complement activity assay, CRF case report form, dsDNA double-stranded DNA, SLE systemic lupus
erythematosus
a Subjective retrospective categorization of patient’s status at baseline by physician
b Multiple responses possible
c Discrepancies in the incidence of high antibody titres and low complement levels between the categories ‘‘laboratory
values’’ and ‘‘SLE manifestations’’ in this table are due to the fact that not all physicians may have considered these laboratory
values as ‘‘manifestations’’. Furthermore, the physicians were asked about laboratory values using a multiple-choice list, while
they were asked about manifestations using an open question. Thus, responses regarding manifestations depended more on
the physicians’ judgment
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disease activity) to 100) showed a mean score of
77.5 ± 11.65 (min 60, max 90). The BILAG
assessment (British Isles Lupus Assessment
Group; results provided as a range from 0 (no
disease activity) to 72) was performed for five
patients with a mean score of 10.2 ± 4.66 (min
5, max 16) at baseline.
Outcomes of Belimumab Therapy After
Initial 6 Months
The patients’ overall clinical response to
belimumab was assessed by their physician
after 6 months of treatment. For the majority
of patients, improvement between 20% and
79% was documented (Fig. 1). An overall
clinical improvement of at least 20% was
observed in 78% of patients and an
improvement of at least 50% in 42% of patients.
When assessing the six most common
clinical and serological manifestations of SLE—
arthritis, increased anti-dsDNA antibody levels,
low complement, fatigue, rash, and alopecia—
most manifestations showed improvement after
6 months of belimumab therapy for the
majority of patients, as assessed by the
physicians (Fig. 2). Notably high improvement
levels were reported for a large proportion of
patients with arthritis and rash, while
complement levels showed the least
improvement overall.
Improvements were also seen in the disease
activity assessments (Table 2). The mean
SLEDAI/SELENA-SLEDAI score decreased from
10.6 to 5.6 during the first 6 months of therapy.
Similarly, most of the other commonly used
indexes, the ECLAM, the Physician Global
Assessment Scale, and the Patient Global
Assessment Scale all showed lower, i.e.,
improved scores after 6 months of belimumab
therapy.
Discontinuations Before End of Initial
6 Months of Belimumab Therapy
Six patients discontinued belimumab treatment
within 6 months; at the time of discontinuation
they had received belimumab for an average of
64 ± 51.85 days (min 15, max 155 days).
Consequently, no results for the time point
after 6 months of belimumab treatment are
available for these patients and they could not
be included in the analyses after 6 months
presented above. The six patients had ratings
of ‘‘worse’’ (four patients), ‘‘no improvement’’






patients (N = 96)
after 6 months of
belimumab therapy,
compared to status at
start of belimumab
treatment
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patient) in the physicians’ evaluation of their
clinical response. In two of these patients a new
induction therapy with cyclosporine or
cyclophosphamide was initiated after the start
of belimumab. Details of the six cases of
discontinuation are presented in Table 3.
Fig. 2 Physicians’ evaluation of clinical response for the
most frequently reported clinical and serological
manifestations of SLE in their patients: improvement
rating after 6 months of belimumab therapy, compared to
status at start of belimumab treatment (arthritis, N = 66;
increased anti-dsDNA antibody levels, N = 52; low
complement levels, N = 44; fatigue, N = 40; rash,
N = 39; alopecia, N = 22; for all 96 patients who
completed the initial 6 months of belimumab)
Table 2 SLE disease activity scores (SLEDAI/SELENA-SLEDAI,
ECLAM, Physician and Patient Global Assessment Scales, BILAG) at
the start of belimumab therapy and after the initial 6 months of
treatment, as well as calculated changes to baseline, for all patients for
whom scores were available for both time points (N = 76)
Assessment tool N Mean score – SD
at baseline
Mean score – SD after
6 months of therapy
Mean change – SD
SLEDAI/SELENA-SLEDAIa 65 10.6 ± 6.09 5.6 ± 4.07 -4.9 ± 4.94
ECLAMb 19 2.9 ± 2.03 1.8 ± 1.70 -1.0 ± 1.40
Physician Global Assessment Scalec 17 71.9 ± 13.56 47.1 ± 19.84 -24.8 ± 18.55
Patient Global Assessment Scalec 8 77.5 ± 11.65 27.5 ± 17.53 -50.0 ± 25.63
BILAGd 5 10.2 ± 4.66 10.2 ± 7.19 0.0 ± 4.53
BILAG British Isles lupus assessment group index, ECLAM European consensus lupus activity measurement index,
N number of patients, SELENA ‘‘Safety of Estrogens in Lupus Erythematosus National Assessment’’ modiﬁcation of
SLEDAI, SLE systemic lupus erythematosus, SLEDAI SLE disease activity index
a (SELENA-)SLEDAI scale: Final score ranges between 0 (no disease activity) and 105
b ECLAM scale: Final score is between 0 (no disease activity) and 10
c Global Assessment Scales based on the physicians’ internal rating system; values were converted to a scale ranging from 0
to 100 based on ranges provided by the physicians
d BILAG range: Final score between 0 (no disease activity) and 72
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Treatment with Other SLE Medications
Before and During Belimumab Treatment
All patients in this study (including those who
discontinued) had undergone treatment with at
least two other SLE medications (mean number
of other medications 5.5 ± 1.96, min 2, max 10)
prior to starting belimumab therapy: for 50% of
the patients, more than five other previous
medications had been documented. All patients
were receiving other SLE medications at the
start and during the 6 months of belimumab
therapy, most commonly oral corticosteroids,
antimalarials, as well as the
immunosuppressants mycophenolate mofetil
and azathioprine. During the first 6 months
with a slowly evolving belimumab effect three
patients also received a new induction
treatment with cyclophosphamide and one
patient has been started cyclosporine. Two of
those patients discontinued belimumab.
The usage of most SLE medications among
the 96 patients who completed the initial
6 months of belimumab treatment remained
stable (Table 4).
A total of 91 patients who completed the
6 months’ course of belimumab therapy
received oral corticosteroids at the start or
during this therapy and were evaluated
regarding their daily corticosteroid intake. A
notable dose reduction of oral corticosteroids
was observed for these patients (Fig. 3).
The mean dose of corticosteroids was
11.7 mg/day 6 months before belimumab
Table 3 Details of patients who discontinued belimumab therapy before the end of the ﬁrst 6 months of belimumab










Reason(s) for discontinuation Corticosteroid
dose changec




2 Moderate 28 \20%
improved




3 Moderate 35 Worse Disease progression No change
(5 mg/day)
4 Unknown 68 Worse Disease progression and ineffective















AE adverse event, SAE serious adverse event, SLE systemic lupus erythematosus, IV intravenous
a SLE improvement from start of belimumab therapy (baseline) to time of discontinuation
b Relationship to belimumab treatment, according to AE reporting form
c Change in dose of concomitant corticosteroid medication from baseline to time of discontinuation
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therapy, 13.7 mg/day at belimumab start, and
7.6 mg/day after 6 months of treatment. A
similar reduction of the mean dose was also
seen when analyzing only those 63 patients
who were being treated with a dose of
corticosteroids of at least 7.5 mg/day at the
start of belimumab treatment (Table 5). Of these
63 patients, 29 had switched to a low dose (less
than 7.5 mg/day) after 6 months of belimumab
therapy. Those 32 patients who remained on a
Table 4 Other medications for SLE that the patients in the OBSErve Germany study received in the 6 months prior to
starting belimumab therapy, at the time of initiating belimumab, and during the therapy (N = 96)




During the ﬁrst 6 months
of belimumab therapy
Number of patients (%) Number of patients (%) Number of patients (%)
Oral corticosteroids 85 (89%) 90 (94%) 88 (92%)
Antimalarials 53 (55%) 57 (59%) 55 (57%)
Mycophenolate mofetil 27 (28%) 25 (26%) 24 (25%)
Azathioprine 17 (18%) 15 (16%) 15 (16%)
Methotrexate 12 (13%) 11 (11%) 8 (8%)
Cyclosporine 9 (9%) 6 (6%) 7 (7%)
NSAIDs 6 (6%) 6 (6%) 5 (5%)
Cyclophosphamide 7 (7%) 1 (1%) 2 (2%)
IV corticosteroids 2 (2%) 1 (1%) 0 (0%)
Thalidomide 1 (1%) 1 (1%) 1 (1%)
Dapsone 1 (1%) 0 (0%) 0 (0%)
IV intravenous, NSAIDs non-steroidal anti-inﬂammatory drugs, SLE systemic lupus erythematosus
a Multiple responses possible
Fig. 3 Number of patients in high and low oral
corticosteroid dose groups, at start of belimumab therapy,
and after the initial 6 months of belimumab therapy (for
all patients who were taking oral corticosteroids and who
completed the initial 6 months of belimumab treatment,
N = 91)
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high dose still showed a reduction in their mean
dose (from 16.0 ± 9.94 to 12.2 ± 7.61 mg/day).
Two patients discontinued oral corticosteroid
use during belimumab treatment. Almost all of
the 27 patients who were on a low
corticosteroid dose (less than 7.5 mg/day) at
the start of belimumab treatment remained on
the low dose, showing a slight decrease in this
dose from 5.3 ± 1.11 to 4.8 ± 1.34 mg/day after
6 months of belimumab therapy. One patient
discontinued oral corticosteroids during this
time and one patient changed from a low to a
high dose. One patient in the study started
taking oral corticosteroids (at least 7.5 mg/day)
during the belimumab treatment period.
Utilization of Other Medications
and Healthcare Resources
During the first 6 months of belimumab
therapy, the use of non-SLE medications
among the 96 patients who completed the
initial 6 months of belimumab therapy
remained relatively constant. The number of
patients requiring SLE-related emergency room
visits dropped from 9% to 3% in the first
6 months of belimumab therapy, as did the
number of SLE-related hospitalizations, with
24% of patients requiring hospitalisation
before start of belimumab therapy in
comparison to 11% of patients during
belimumab treatment (Table 6). While the
number of scheduled visits to the physician’s
practice per patient increased during
belimumab therapy due to the infusions, the
number of unscheduled visits was reduced
overall.
DISCUSSION
The OBSErve Germany study reflects the
real-world practice of treating SLE with
belimumab after its approval in Germany
2011. As a result of its purely retrospective
character and the methodological approach, the





corticosteroid ‡7.5 mg/day at
belimumab start (N5 63)a
Patients on
corticosteroid <7.5 mg/day at
belimumab start (N5 27)a
Mean dose (±SD) 6 months
before belimumab start
(mg/day)
11.7 ± 15.00 12.6 ± 13.25 10.2 ± 18.73
Mean dose (±SD) at belimumab
start (mg/day)
13.7 ± 13.75 17.5 ± 15.04 5.4 ± 1.11
Mean dose (±SD) after ﬁrst
6 months of belimumab
therapy (mg/day)
7.6 ± 5.99 8.6 ± 6.63 5.2 ± 3.36
Data are shown for all patients who received oral corticosteroids at one of these time points and who completed the initial
6 months of belimumab therapy (N = 91), as well as for all patients who initiated belimumab treatment while taking a
dose C7.5 mg/day (N = 63) or a low dose (N = 27) of oral corticosteroids
a One patient initiated corticosteroid intake after start of belimumab therapy and was therefore only included in the ‘‘Total’’
column, not in the subgroups by starting dose
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results are only descriptive for the patients
included and no formal conclusions regarding
the effectiveness and tolerability of belimumab
can be drawn for populations other than this.
The OBSErve Germany study aimed to
elucidate how belimumab is being used in
routine clinical care in Germany (its initiation
and discontinuation), 2 years after its marketing
authorization. The patient data included in the
study were sourced from 21 clinical sites with
experience not only in treating SLE patients but
also in prescribing belimumab. The
demography of the patient population was as
expected for SLE patients in Germany,
including predominantly white females [27].
Most of the 102 documented patients had been
living with SLE for a number of years and had
moderate or severe disease. Many of them were
serologically active with high levels of
anti-dsDNA antibodies and below-normal
levels of complement components in their
blood and were suffering from several clinical
SLE manifestations like arthritis, nephritis or
rash, and from other co-morbid conditions such
as fatigue, hypertension, and osteoporosis.
Belimumab therapy was most commonly
initiated because previous treatments had been
regarded as ineffective. Thus, the study
population included mainly patients with a
long and severe SLE history not sufficiently
controlled by other medications. Reflecting
this, all patients had been taking a number of
other SLE medications before starting
belimumab therapy and also continued taking
other drugs along with belimumab, most
frequently oral corticosteroids. In 26 patients a
manifestation of mild lupus nephritis was
present together with other manifestations. Of
note, belimumab is not recommended in
patients with severe acute renal involvement
(serum creatinine greater than 2.5 mg/dl,
proteinuria greater than 6 g/day) or acute
neuropsychiatric lupus, that were not present
in our cohort. Overall, the baseline
characteristics showed that belimumab is
being prescribed appropriately in routine care;
it is indicated as an additional therapeutic
measure for patients with high disease activity
Table 6 Unscheduled health resources utilization documented for the SLE patients in the OBSErve Germany study during
the initial 6 months of belimumab therapy, in comparison to the 6 months before start of belimumab treatment (N = 96)
During the 6 months before start of
belimumab therapy
During the initial 6 months of
belimumab therapy
Number of patients % of patients Number of patients % of patients
SLE-related emergency room visits
Yes 9 9 3 3
No 1 1 7 7
Hospitalizations
C2 8 8 0 0
1 15 16 11 11
0 (or date unknown) 73 76 85 89
Hospitalization related to belimumab 0 0 0 0
SLE systemic lupus erythematosus
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based on clinical and laboratory parameters
who show autoreactive antibodies and who
have not responded sufficiently to other SLE
treatments [13]. Owing to the relatively large
sample size (about one-third of all patients
being treated with belimumab in Germany at
that time) and the efforts to minimize selection
bias by including all eligible patient records at
each participating site, the results provide a first
indication of the belimumab treatment
situation in Germany between 2011 and 2013,
with a documentation period from April to
November 2013.
The patients’ clinical outcomes after
6 months of belimumab treatment were
evaluated by the participating physicians on
the basis of their patients’ medical records. On
the one hand, the physicians provided a
subjective assessment of their individual
patients’ SLE status improvement after
belimumab treatment based on a
non-validated but true-to-life scale. On the
other hand this outcome assessment often was
complemented by standardized disease activity
scores. The physicians’ judgment was favorable
for the majority of patients, with 74% of
patients showing an overall SLE status
improvement of at least 20% and 42% of
patients an improvement of at least 50%.
Similarly, most of the frequent clinical and
serological manifestations showed
improvements after 6 months, as assessed by
the responsible physician. In addition, 19 of the
participating 21 physicians stated that they
defined a priori treatment targets allowing the
measurement of the achievements against the
targets and to use formal disease activity scores
on a regular basis as recommended by
international guidelines (e.g., EULAR) [26].
Therefore, results from such scores are
available for 79 of the 102 patients in this
study, possibly indicating a recently extended
use of these tools, at least for the newer and
more expensive treatment options. The most
commonly used scores were the SLEDAI/
SELENA-SLEDAI, the ECLAM, the Patient
Global Assessment Scale, and the Physician
Global Assessment Scale, all of which showed
lower, i.e., improved, scores after 6 months of
belimumab therapy. This combination of
subjective physicians’ assessments and
validated disease activity indexes appears to
reflect a positive trend in clinical SLE
management; new composite response indexes
which incorporate the physicians’ assessment
have recently been developed [28]. The world’s
largest as yet conducted lupus studies, the
randomized controlled BLISS trials with
belimumab, used the Physician Global
Assessment (PGA) as part of the combined SRI
index (SLE Responder Index) [29]. The SRI,
however, is not feasible for the assessment of
lupus activity in daily clinical routine practice
mainly because of its BILAG part. In contrast,
the PGA, as a subjective and non-standardized
evaluation of effectiveness, still is the basis for
most treatment decisions. The fact that the
subjective assessment of disease activity is
consistent with the results from formal scores
and that the validated tools are being used on a
regular basis for the majority of patients
documented in the OBSErve Germany study
may indicate that the recommended approach
of systematically assessing a patient’s condition
over time is becoming more common in clinical
practice. This is a real-world finding of OBSErve
Germany that complements the more
controlled objectives addressed by the clinical
trials.
Consistent with the clinical outcomes, a
reduction in the use of oral corticosteroid
medication was also observed. The association
of corticosteroids with severe side effects at
higher doses (at least 7.5 mg/day; [30]) makes
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any corticosteroid reduction to at least below
this threshold one of the key therapeutic targets
in SLE management [7]. After the initial
6 months of belimumab therapy, the mean
dose of corticosteroids taken by the patients
had decreased markedly and more than half of
the patients who had entered belimumab
treatment on a high dose of corticosteroids
were able to change to a low dose. While the
randomized clinical trials with belimumab were
not designed to show a steroid-sparing effect,
the OBSErve Germany results contribute to the
growing set of data describing such outcomes. If
the potential link between belimumab
treatment and corticosteroid sparing can be
proven in further clinical or observational
studies, it will be highly relevant for the
management of SLE patients, especially for
those who do not cope well with the side
effects of corticosteroids and/or who could not
achieve a dose within an acceptable range
before. In contrast to the corticosteroid intake,
the use of other concomitant medications was
not reduced in this study.
Finally, the extent of utilization of
healthcare resources was evaluated for the
study population. As an innovative antibody
therapy, belimumab treatment is more costly
than other SLE medications. However, its
benefits appear to impact other healthcare
resources in routine clinical care. In the
OBSErve Germany study, the patients required
fewer SLE-related emergency room visits and
fewer SLE-related hospitalizations in the
6 months of belimumab therapy than in the
6 months before. The number of scheduled
visits of patients at their physician’s practice
increased on average, as expected during the
course of belimumab, which requires
administration as monthly infusions. The
number of unscheduled visits, on the other
hand, was reduced. Overall, it appears that
belimumab-treated patients have fewer
SLE-related emergencies and that their SLE
activity management is improved within the
first 6 months of the treatment.
OBSErve Germany was a non-interventional
study. Such investigations have certain inherent
strengths (e.g., the real-world perspective,
potentially large patient populations, longer
investigation periods) as well as limitations
(e.g., no stringent evaluation of efficacy, no
source data verification, possible issues with
availability and comparability of diagnostic
data, limited control of confounding effects)
in comparison to clinical trials [31]. As
discussed above, the real-world setting
provided insights into how belimumab is used
in routine care, when no protocol or
monitoring is required. Interference with the
physicians’ procedures was impossible because
of the retrospective data collection. The data
provided by the physicians were checked for
plausibility but not verified in the source
documents. No control group was set up.
Consequently, no direct conclusions regarding
the efficacy and safety of belimumab can be
drawn. Nevertheless, the results of the OBSErve
Germany study do indicate good effectiveness
and the low number of discontinuations due to
adverse events (AEs) indicates good tolerability,
in line with the clinical trials where efficacy and
safety were confirmed previously.
OBSErve Germany was designed with a
different focus; complementary to the pivotal
studies it is important to understand the
practicalities of belimumab treatment,
outcomes, and discontinuations under
real-world conditions to determine the clinical
value of this new therapy and its potential
impact on SLE management [25]. A detailed
profile of those patients that respond
particularly well to belimumab treatment can
shape future treatment guidelines and help
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physicians identify the right treatment for a
patient. SLE is a disease where many patients
rely on a combination of two or three
medications to manage disease activity.
Therefore, the effect of belimumab on the
concomitant SLE medication may be of
interest in further investigations covering a
longer time period. Compared to the patient
population in the BLISS studies [14, 15], the
patients documented in the OBSErve Germany
study had a higher mean disease activity. The
observations described here are highly
consistent with a subgroup analysis of the
BLISS patients which shows that patients with
higher disease activity are the ones responding
best to belimumab [16]. On the basis of these
results, further SLE subgroups may be of interest
for assessing the risks and benefits of
belimumab treatment. For example, a large
clinical trial is currently ongoing to investigate
belimumab treatment outcomes specifically for
adult patients with active lupus nephritis.
As a result of the retrospective and
observational nature of the OBSErve study,
safety data were not collected in detail.
However, the data on discontinuations may
provide some insight into safety aspects. Six of
the 102 study patients discontinued belimumab
treatment within 6 months. For three of these
patients, their physicians documented ‘‘disease
progression’’ and ‘‘ineffective medication’’ as
the reasons for withdrawing belimumab. In
these patients, treatment was discontinued
after 16, 35, and 68 days, respectively, i.e.,
within the first 10 weeks. This is a point in
time where the full clinical effect of belimumab
cannot yet be expected. As s result of its mode of
action and supported by the clinical study
results, a minimum treatment period of
6 months is recommended in the summary of
product characteristics for belimumab [13], to
allow full efficacy to develop before a decision
regarding further therapy is made. In the three
patients described here, the constellation of
their course of disease and their concomitant
corticosteroid doses at least leaves some
questions open, one of them being whether
more patience regarding the development of
the therapeutic effects could have led to
different treatment results. Two of the patients
discontinued because of an adverse event, one
of which was an allergic reaction. This is
consistent with the summary of product
characteristic for belimumab, which describes
that 1% of belimumab study patients are
withdrawn from the treatment because of an
allergic reaction [13]. For the one patient who
died, no causal relationship to belimumab was
suspected.
These results are consistent with the
conclusion from the clinical trials that
belimumab is generally well tolerated
although this study did not collect safety data
besides those leading to withdrawal [32]. As
with other immunomodulatory drugs or
antibody therapies, patient monitoring
remains important, however, especially during
and after the first exposures.
Overall, the effectiveness of belimumab seen
in the OBSErve Germany study exceeded the
expectations from the pivotal trials [14–16] with
regards to the extent of clinical improvement
and to its onset. Whether this is a real effect or a
methodological bias due to the high hurdles to
achieve the primary endpoints in clinical
studies needs to be evaluated further. Very
similar results have been presented for patients
in Spain and in the USA (OBSErve Spain,
published in an abstract [24]; OBSErve US
[23]). Other, smaller-scale studies assessing the
effectiveness of belimumab in a real-world
setting have also confirmed belimumab as an
option for patients not sufficiently controlled
by conventional therapies [33–37].
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CONCLUSIONS
The OBSErve Germany study provides the first
insight into belimumab use and outcomes for
SLE patients in Germany, 2 years after its market
launch. The real-world results reveal that, after
6 months of belimumab treatment, disease
activity as well as concomitant oral
corticosteroid use was reduced in the study
population of patients that mostly had
moderate or severe SLE and elevated
autoreactive antibody levels. The low rate of
discontinuation supports the good general
tolerability of belimumab. Overall and despite
all limitations described, belimumab is showing
promising real-world results and a broad
treatment response for the patient group
investigated, in line with the results from the
pivotal trials. Such a new therapeutic option for
a subgroup of patients with higher disease
activity is particularly valuable in the context
of a variable disease like SLE, where the unmet
medical need still is high, the quality of life
markedly reduced for the affected patients, and
for which no other new therapies have been
approved for decades.
ACKNOWLEDGEMENTS
OBSErve Germany was sponsored by
GlaxoSmithKline, Uxbridge, UK and
conducted by Kantar Health GmbH, Munich,
Germany, including study coordination by
Constanze Cholmakow-Bodechtel and Claudia
Kanitscheider, statistical analyses by Marian
Schmidt and Hans-Jo¨rg Schwarz, and medical
writing assistance by Sarah Hemer and Daniela
Tonn of Kantar Health. Medical writing
assistance as well as the publication charges
of this article were funded by
GlaxoSmithKline, Uxbridge, UK. All authors
had full access to all of the data in this study
and take complete responsibility for the
integrity of the data and accuracy of the data
analysis. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
manuscript, take responsibility for the integrity
of the work as a whole, and have given final
approval for the version to be published. The
authors thank all further participating
investigators: Prof Dr. Hans-Joachim Anders,
Dr. Peer M. Aries, Dr. Gunther Aßmann, Dr.
Frank Behrens, Dr. Ino K. Gao, Dr. Jo¨rg Henes,
Prof Dr. Annett Jacobi, Dr. Helge Ko¨rber, Dr.
Kirsten Lu¨thke, Prof Dr. Peter Oelzner, Dr. Elke
Riechers, PD Dr. Ekkehard Ro¨ther, Dr.
Christoph Scha¨fer, Dr. Astrid M. Thiele, Prof
Dr. Hans-Peter Tony, Prof Dr. Stefan Weiner.
Disclosures A. Schwarting received personal
fees from GSK during the conduct of the study.
A. Schwarting also reports grants and personal
fees from GSK, outside the submitted work.
C. Fiehn received personal fees from GSK during
the conduct of the study. J.O. Schroeder
received personal fees from GSK during the
conduct of the study. J.O. Schroeder also reports
personal fees from GSK, outside the submitted
work. M. Schmalzing received personal fees
from GSK during the conduct of the study.
T. Alexander received personal fees from GSK
during the conduct of the study. C. Specker
reports personal fees from GSK outside the
submitted work. A. Perna is an employee of
GSK and holds equity ownership in the
company. H. Carnarius is an employee of GSK
and holds equity ownership in the company.
V. Koscielny was at the time of the study and
manuscript preparation a GSK employee and
held equity ownership in the company.
C. Cholmakow-Bodechtel is an employee of
Kantar Health.
288 Rheumatol Ther (2016) 3:271–290
Compliance with Ethics Guidelines This
article does not contain any new studies with
human or animal subjects performed by any of
the authors.
Open Access This article is distributed under
the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommercial
use, distribution, and reproduction in any
medium, provided you give appropriate credit to
the original author(s) and the source, provide a
link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. Houssiau FA, Vasconcelos C, D’Cruz D, et al. Early
response to immunosuppressive therapy predicts
good renal outcome in lupus nephritis: lessons
from long-term followup of patients in the
Euro-Lupus Nephritis Trial. Arthritis Rheum.
2004;50(12):3934–40.
2. Ginzler EM, Dooley MA, Aranow C, et al.
Mycophenolate mofetil or intravenous
cyclophosphamide for lupus nephritis. N Engl J
Med. 2005;353(21):2219–28.
3. Lutalo PMK, Jordan N, D’Cruz DP. Which dose of
steroids and which cytotoxics for severe lupus?
Presse Med. 2014;(6 Pt 2):e157–65.
4. Nørgaard JC, Stengaard-Pedersen K, Nørgaard M, de
Thurah A. Antimalarials in the treatment of
systemic lupus erythematosus: a registry-based
cohort study in Denmark. Lupus.
2015;24(3):299–306.
5. Petri M, Bechtel B, Dennis G, et al. Burden of
corticosteroid use in patients with systemic lupus
erythematosus: results from a Delphi panel. Lupus.
2014;23(10):1006–13.
6. Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I,
Medina JA, Moran MA, Ruiz-Irastorza G.
Glucocorticoids and irreversible damage in
patients with systemic lupus erythematosus.
Rheumatol (Oxford). 2014;53(8):1470–6.
7. Van Vollenhoven RF, Mosca M, Bertsias G, et al.
Treat-to-target in systemic lupus erythematosus:
recommendations from an international task
force. Ann Rheum Dis. 2014;73(6):958–67.
8. Brugos B, Sebestyen L, Tarr T, Vincze Z. Use of
cyclophosphamide and other immunosuppressive
drugs in the treatment of patients with lupus
nephritis. Pharm. 2014;69(6):442–4.
9. Chan TM. Treatment of severe lupus nephritis: the
new horizon. Nat Rev Nephrol. 2015;11(1):46–61.
10. Leone A, Sciascia S, Kamal A, Khamashta M.
Biologicals for the treatment of systemic lupus
erythematosus: current status and emerging
therapies. Expert Rev Clin Immunol.
2015;11(1):109–16.
11. Kamal A, Khamashta M. The efficacy of novel B cell
biologics as the future of SLE treatment: a review.
Autoimmun Rev. 2014;13(11):1094–101.
12. Selmi C, Generali E, Massarotti M, Bianchi G, Scire´
CA. New treatments for inflammatory rheumatic
disease. Immunol Res. 2014;60(2–3):277–88.




human/002015/WC500110150.pdf. Accessed 15 Dec
2016.
14. Furie R, Petri M, Zamani O, et al. A phase III,
randomized, placebo-controlled study of
belimumab, a monoclonal antibody that inhibits
B lymphocyte stimulator, in patients with systemic
lupus erythematosus. Arthritis Rheum.
2011;63(12):3918–30.
15. Navarra SV, Guzma´n RM, Gallacher AE, et al.
Efficacy and safety of belimumab in patients with
active systemic lupus erythematosus: a randomised,
placebo-controlled, phase 3 trial. Lancet.
2011;377(9767):721–31.
16. Van Vollenhoven RF, Petri MA, Cervera R, et al.
Belimumab in the treatment of systemic lupus
erythematosus: high disease activity predictors of
response. Ann Rheum Dis. 2012;71(8):1343–9.
17. Parodis I, Axelsson M, Gunnarsson I. Belimumab
for systemic lupus erythematosus: a practice-based
view. Lupus. 2013;22(4):372–80.
18. Askanase AD, Yazdany J, Molta CT. Post-marketing
experiences with belimumab in the treatment of
SLE patients. Rheum Dis Clin North Am.
2014;40(3):507–17.
19. Lutalo PMK, D’Cruz DP. Update on belimumab for
the management of systemic lupus erythematosus.
Expert Opin Biol Ther. 2014;14(11):1701–8.
Rheumatol Ther (2016) 3:271–290 289
20. Baker KP, Edwards BM, Main SH, et al. Generation
and characterization of LymphoStat-B, a human
monoclonal antibody that antagonizes the
bioactivities of B lymphocyte stimulator. Arthritis
Rheum. 2003;48(11):3253–65.
21. Cancro MP, D’Cruz DP, Khamashta MA. The role of
B lymphocyte stimulator (BLyS) in systemic lupus
erythematosus. J Clin Investig.
2009;119(5):1066–73.
22. Stohl W, Hiepe F, Latinis KM, et al. Belimumab
reduces autoantibodies, normalizes low
complement, and reduces select B-cell populations
in patients with systemic lupus erythematosus.
Arthritis Rheum. 2012;64(7):2328–37.
23. Collins CE, Dall’Era M, Kan H, et al. Response to
belimumab among patients with systemic lupus
erythematosus in clinical practice settings:
24-month results from the OBSErve study in the
USA. Lupus Sci Med. 2016;3:e000118. doi:10.1136/
lupus-2015-000118.
24. Cortes J, Andreu JL, Calvo-Alen J, et al. Evolution of
patients with systemic lupus erythematous treated
with belimumab in clinical practice settings.
Arthritis Rheumatol. 2014;66(Suppl 11):S291.
25. Mosca M, van Vollenhoven R. New drugs in
systemic lupus erythematosus: when to start and
when to stop. Clin Exp Rheumatol. 2013;31(4 Suppl
78):S82–5.
26. Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR
recommendations for the management of systemic
lupus erythematosus. Report of a Task Force of the
EULAR Standing Committee for International
Clinical Studies Including Therapeutics. Ann
Rheum Dis. 2008;67(2):195–205.
27. Cervera R, Doria A, Amoura Z, et al. Patterns of
systemic lupus erythematosus expression in Europe.
Autoimmun Rev. 2014;13(6):621–9.
28. Rao V, Gordon C. Advances in the assessment of
lupus disease activity and damage. Curr Opin
Rheumatol. 2014;26(5):510–9.
29. Furie RA, Petri MA, Wallace DJ, et al. Novel
evidence-based systemic lupus erythematosus
responder index. Arthritis Rheum.
2009;61(9):1143–51.
30. Ruiz-Irastorza G, Danza A, Khamashta M.
Glucocorticoid use and abuse in SLE. Rheumatol
(Oxford). 2012;51(7):1145–53.
31. Silverman SL. From randomized controlled trials to
observational studies. Am J Med.
2009;122(2):114–20.
32. Wallace DJ, Navarra S, Petri MA, et al. Safety profile
of belimumab: pooled data from placebo-controlled
phase 2 and 3 studies in patients with systemic
lupus erythematosus. Lupus. 2013;22(2):144–54.
33. Askanase AD. Clinical response to belimumab in
academic clincal practices. Ann Rheum Dis.
2014;73(Suppl 2):521–2.
34. Brito Zeron P, Caminal-Montero L, Chamorro A,
et al. Blocking the human B lymphocyte stimulator
molecule (BLyS) using a monoclonal antibody
(belimumab) in Systemic lupus erythematosus:
first results in real-life spanish patients with
refractory disease (biogeas-Semi Registry). Ann
Rheum Dis. 2014;73(Suppl 2):985.
35. Ke X, Patel J, Kan H, Eisenberg DF, Oglesby A.
Characteristics and medication use patterns among
belimumab users in a commercially insured
population with systemic lupus erythematosus.
Arthritis Rheum. 2013;65(Suppl 10):1070.
36. Iaccarino L, Bettio S, Ghirardello A, et al.
Preliminary data on the efficacy of belimumab in
the ‘‘real-Life’’: a single centre experience.
Proceedings of the 9th international congress on
autoimmunity; 2014 26–30 March; Nice, France.
37. Majdan M, Kucharz EJ, Jeka S, Sierakowski S,
Leszczynski P, Tlustochowicz W, et al. Early
clinical experiences with belimumab in Polish
patients with systemic lupus erythematosus. Ann
Rheum Dis. 2014;73(Suppl 2):970.
290 Rheumatol Ther (2016) 3:271–290
